IP Library Patent Application 17219039
Patent Application
App. No. 17/219,039

STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/219,039
Abstract

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.

Claims (10)

1 . A method of reducing triglycerides in a subject having a fasting baseline triglyceride level of at least about 700 mg/dl, atrial fibrillation and/or atrial flutter, and on a statin therapy, the method comprising administering to the subject about 4 g of ethyl eicosapentaenoate per day.

2 . The method of claim 1 , wherein the ethyl eicosapentaenoate is present in a pharmaceutical composition and the ethyl eicosapentaenoate comprises at least about 96 wt. % of all omega-3 fatty acids in the pharmaceutical composition.

3 . The method of claim 2 , wherein about 1 g of the pharmaceutical composition is present in each of 4 capsules.

4 . The method of claim 1 , wherein the subject has a baseline LDL-C level of about 40 mg/dL to about 100 mg/dL.

5 . The method of claim 1 , wherein the subject is diabetic.

6 . The method of claim 1 , wherein the subject exhibits at least about a 10% reduction in fasting triglycerides compared to a baseline triglyceride level.

7 . The method of claim 6 , wherein the subject exhibits no statistically significant increase in LDL-C compared to an LDL-C level prior to initial administration of the ethyl eicosapentaenoate.

8 . The method of claim 2 , wherein the statin therapy is a stable statin therapy.

9 . The method of claim 2 , wherein the subject is administered the ethyl eicosapentaenoate for at least about 12 weeks.

10 . The method of claim 2 , further comprising reducing a risk of stroke, myocardial infarction, or both in the subject.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 055789 FRAME: 0102. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Apr 5, 2021
From: MANKU, MEHAR; OSTERLOH, IAN; WICKER, PIERRE; BRAECKMAN, RENE; SONI, PARESH
To: AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 055822/0423 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2021
From: MANKU, MEHAR; OSTERLOH, IAN; WICKER, PIERRE; BRAECKMAN, RENE; SONI, PARESH
To: AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 055789/0102 →